Tags

Type your tag names separated by a space and hit enter

Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma.
Am J Respir Crit Care Med. 2000 Jul; 162(1):40-4.AJ

Abstract

It is unclear whether angiotensin II receptors are involved in bronchial hyperresponsiveness in asthmatic patients. We examined the effect of losartan, a specific angiotensin II type 1 (AT1) receptor antagonist, on bronchial responsiveness to inhaled methacholine in eight patients with stable asthma. Bronchial responsiveness to methacholine, assessed as the concentration of methacholine producing a 20% fall in FEV(1) (PC(20)-FEV(1)) and a 35% fall in standardized partial expiratory flow at 40% of FVC (PC(35)-PEF(40)), was measured on two occasions 2 wk apart. Losartan (50 mg once a day) or a placebo was orally administered for 1 wk before methacholine provocation test in a double-blind, randomized, crossover fashion. Although the PC(20)-FEV(1) values after placebo (2.037 [geometric standard error of the mean, GSEM = 0.210] mg/ml) and losartan (2.098 [GSEM, 0.239] mg/ml) were identical (p = 0.840), the geometric mean PC(35)-PEF(40) values significantly (p = 0.034) increased from 0.258 (GSEM, 0.156) mg/ml with placebo to 0.456 (GSEM, 0.186) mg/ml with losartan. We conclude that AT1 receptors are involved in bronchial hyperresponsiveness in asthmatic patients. This is the first report demonstrating the involvement of AT1 receptors in bronchial asthma.

Authors+Show Affiliations

Third Department of Internal Medicine and Department of Laboratory Medicine, Kanazawa University School of Medicine, Kanazawa, Japan. myous@p2222.nsk.ne.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

10903217

Citation

Myou, S, et al. "Effect of Losartan, a Type 1 Angiotensin II Receptor Antagonist, On Bronchial Hyperresponsiveness to Methacholine in Patients With Bronchial Asthma." American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 1, 2000, pp. 40-4.
Myou S, Fujimura M, Kamio Y, et al. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care Med. 2000;162(1):40-4.
Myou, S., Fujimura, M., Kamio, Y., Ishiura, Y., Kurashima, K., Tachibana, H., Hirose, T., & Hashimoto, T. (2000). Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. American Journal of Respiratory and Critical Care Medicine, 162(1), 40-4.
Myou S, et al. Effect of Losartan, a Type 1 Angiotensin II Receptor Antagonist, On Bronchial Hyperresponsiveness to Methacholine in Patients With Bronchial Asthma. Am J Respir Crit Care Med. 2000;162(1):40-4. PubMed PMID: 10903217.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. AU - Myou,S, AU - Fujimura,M, AU - Kamio,Y, AU - Ishiura,Y, AU - Kurashima,K, AU - Tachibana,H, AU - Hirose,T, AU - Hashimoto,T, PY - 2000/7/21/pubmed PY - 2000/9/19/medline PY - 2000/7/21/entrez SP - 40 EP - 4 JF - American journal of respiratory and critical care medicine JO - Am. J. Respir. Crit. Care Med. VL - 162 IS - 1 N2 - It is unclear whether angiotensin II receptors are involved in bronchial hyperresponsiveness in asthmatic patients. We examined the effect of losartan, a specific angiotensin II type 1 (AT1) receptor antagonist, on bronchial responsiveness to inhaled methacholine in eight patients with stable asthma. Bronchial responsiveness to methacholine, assessed as the concentration of methacholine producing a 20% fall in FEV(1) (PC(20)-FEV(1)) and a 35% fall in standardized partial expiratory flow at 40% of FVC (PC(35)-PEF(40)), was measured on two occasions 2 wk apart. Losartan (50 mg once a day) or a placebo was orally administered for 1 wk before methacholine provocation test in a double-blind, randomized, crossover fashion. Although the PC(20)-FEV(1) values after placebo (2.037 [geometric standard error of the mean, GSEM = 0.210] mg/ml) and losartan (2.098 [GSEM, 0.239] mg/ml) were identical (p = 0.840), the geometric mean PC(35)-PEF(40) values significantly (p = 0.034) increased from 0.258 (GSEM, 0.156) mg/ml with placebo to 0.456 (GSEM, 0.186) mg/ml with losartan. We conclude that AT1 receptors are involved in bronchial hyperresponsiveness in asthmatic patients. This is the first report demonstrating the involvement of AT1 receptors in bronchial asthma. SN - 1073-449X UR - https://www.unboundmedicine.com/medline/citation/10903217/Effect_of_losartan_a_type_1_angiotensin_II_receptor_antagonist_on_bronchial_hyperresponsiveness_to_methacholine_in_patients_with_bronchial_asthma_ L2 - http://www.atsjournals.org/doi/full/10.1164/ajrccm.162.1.9907127?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -